

# MS Treatments

## Resource Rich versus Resource Challenged Regions

---



# Disclosures

- I have received advisory board or speaker fees from Alexion, Novartis, Sanofi, Vindico, and Healion Live
- I have no conflicts of interest with the content of this presentation
- Off label therapies germane to the topic of this talk will be mentioned

# Objectives

- To discuss current recommendations regarding disease modifying therapies (DMTs) for people living with MS (PwMS)
- To highlight worldwide socioeconomic disparities in care regarding MS treatment & DMT access
- To outline emerging strategies to promote equitable access to care for PwMS

# Key Findings

---

- The estimated number of PwMS worldwide increased to 2.8 million in 2020
- The recent MS International Federation (MSIF) Atlas of MS survey showed that 72% of countries have major barriers to accessing DMTs for PwMS
- Off-label DMTs for MS are used in at least 89 countries
- Guidelines are needed for clinical decision-making, pharmaceutical policies, and reimbursement decisions for use of off-label DMTs
- Global advocacy and collaboration will be required to promote ethical and equitable access to care for all PwMS, including those in resource challenged regions of the world

# References

---

1. Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, Robertson N, La Rocca N, Uitdehaag B, van der Mei I, Wallin M, Helme A, Angood Napier C, Rijke N, Baneke P. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. *Mult Scler* 2020 Dec;26(14):1816-1821.
2. McDonnell J, Costello K, Laurson-Doube J, et al. World Health Organization essential medicines list: Multiple sclerosis disease-modifying therapies application. *Mult Scler* 2020; 26(2): 153–158.
3. Laurson-Doube J, Rijke N, Helme A, Baneke P, Banwell B, Viswanathan S, Hemmer B, Yamout B. Ethical use of off-label disease-modifying therapies for multiple sclerosis. *Mult Scler* 2021 Aug;27(9):1403-1410.
4. Laurson-Doube J, Rijke N, Costello K, et al. Health-care disparities for people with multiple sclerosis. *Lancet Neurol* 2020; 19(3): 207–208.
5. Atlas of MS. Available at: <https://www.atlasofms.org/> (accessed September 5, 2023).
6. <https://www.msif.org/news/2023/07/25/whos-decision-brings-hope-to-people-with-ms-worldwide/> (accessed September 5, 2023).